Lupin launches Atorvastatin Calcium Tablets USP

Product manufacturing to start at Lupin's Nagpur facility

0
259
Lupin
Photo by Amanda Jones on Unsplash

Mumbai headquartered pharma company Lupin announced the launch of Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg, receiving approval from the United States Food and Drug Administration (USFDA) earlier. The product will be manufactured at Lupin’s Nagpur facility in India.

Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg, is the generic equivalent of Lipitor Tablets, 10 mg, 20 mg, 40 mg, and 80 mg, of Pfizer, and indicated to lower cholesterol in the blood for adults and children over ten years of age. Atorvastatin is also prescribed to lower the risk of heart attack and stroke in patients with cardiovascular diseases, diabetes, and other risk factors such as eye problems, kidney diseases, or high blood pressure.

According to IQVIA MAT, July 2020 report, Atorvastatin Calcium Tablets USP (RLD: Lipitor) had annual sales of approximately US$ 559 million in the U.S.

Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and the Middle-East regions.

The company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments. It has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the 3rd largest pharmaceutical company in the U.S. by prescriptions and 5th in India by global revenues. The company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology and Pharmaceuticals sector.

LEAVE A REPLY

Please enter your comment!
Please enter your name here